15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 13 firms covering Denali Therapeutics Inc, 12 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $23.00 to $42.00, a moderate spread. The average target of $34.36 sits 46% above the current $23.57. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.64 next quarter toward $-2.53 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 ratings
Moderate Buy
Strong Buy00%
Buy1292%
Hold18%
Sell00%
Strong Sell00%
Based on 13 analysts giving stock ratings to Denali Therapeutics Inc.
As of Jul, 12 of 13 firms rate DNLI a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
DNLI EPS & revenue forecast
EPS · NEXT QUARTER
$-0.64
Range $-0.90 – $0.17 · 15 analysts · -13% YoY
Next period, 15 analysts expect Denali Therapeutics Inc to earn $-0.64 a share (range $-0.90 – $0.17), versus $-0.74 a year earlier. Full-year consensus is $-2.37, growing to $-2.53 the year after.
REVENUE · NEXT QUARTER
$5.5M
Range $1.4M – $27.1M · 15 analysts
Revenue is expected to reach $5.5M (range $1.4M – $27.1M). Full-year consensus is $34.0M, rising to $103.7M next year.
Top analysts covering Denali Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DNLI.
#1
Mayank Mamtani
B. Riley Securities · Rank #9
Buy
$30.00+27.3% to target
Overall win rate
53%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #35
Buy
$42.00+78.2% to target
Overall win rate
46%
+ Follow
#3
Jessica Fye
JP Morgan · Rank #64
Buy
$29.00+23.0% to target
Overall win rate
52%
+ Follow
#4
Joel Beatty
Baird · Rank #111
Buy
$34.00+44.3% to target
Overall win rate
46%
+ Follow
#5
Laura Chico
Wedbush · Rank #122
Buy
$26.00+10.3% to target
Overall win rate
40%
+ Follow
DNLI stock forecast FAQ
What is DNLI's average 12-month price target?+
The 11 analysts with a live target average $34.36 for Denali Therapeutics Inc over the next 12 months, ranging from a $42.00 high to a $23.00 low.
Is DNLI stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 13 analyst ratings, 12 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for DNLI?+
The Street-high target is $42.00 (HC Wainwright & Co.), and the Street-low is $23.00 (Wedbush). The average of all 11 active targets is $34.36.
How many Wall Street analysts cover DNLI?+
13 analysts have an active rating on Denali Therapeutics Inc, and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering DNLI?+
Among analysts who currently cover DNLI, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #9). Their current call is Buy with a $30.00 target.
What is Denali Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.64 per share (range $-0.90 – $0.17) across 15 analysts. Full-year EPS is projected at $-2.37, rising to $-2.53 the following year.
How much revenue is Denali Therapeutics Inc expected to report next quarter?+
Consensus revenue is $5.5M (range $1.4M – $27.1M). Full-year revenue is projected at $34.0M, growing to $103.7M next year.
Have analysts been upgrading or downgrading DNLI lately?+
As of Jul, 12 of 13 firms rate DNLI a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DNLI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
